H.R. 1329 Falls to 19% Despite 163 Bipartisan Cosponsors
H.R. 1329 lost 20 percentage points in three days with no negative catalyst; Kalshi prices it at 16%, Polymarket at 22%.
The Bipartisan Dream That Prediction Markets Are Betting Against
H.R. 1329, the Smithsonian American Women's History Museum Act, has 163 cosponsors: 82 Republicans and 81 Democrats. That near-perfect partisan split is the kind of coalition that legislative strategists fantasize about. The bill, introduced by Representative Nicole Malliotakis, would authorize the museum's location within the Reserve of the National Mall, advancing a project that Congress itself established in December 2020. The House Natural Resources Committee held a hearing on the bill in February 2026. No opposition testimony made headlines. No competing bill emerged to undercut it.
And yet traders on Kalshi and Polymarket have cut the bill's implied probability of becoming law in 2026 from 39% to 19% over just three days. That is a halving of market confidence with no identifiable negative catalyst. No floor vote was blocked. No leadership statement torpedoed the bill. The most recent legislative development, a public lands hearing in February, was procedurally normal. The price action is telling a story that the news cycle is not.
Live Odds: What the Market Is Pricing Right Now
The current implied probability of H.R. 1329 becoming law by December 31, 2026, sits at 19%. That figure represents the blended read across two platforms. Kalshi prices the bill at 16%. Polymarket prices it at 22%. The 6-percentage-point spread between the two platforms reflects a pattern common in political legislation markets: Polymarket's slightly higher price likely reflects a more retail-heavy user base that weights cosponsor counts more heavily, while Kalshi's institutional lean discounts them.
A 20-percentage-point drop in three days, from 39% to 19%, is a breakout move by any standard. In bill-passage markets, which tend to drift rather than spike, this magnitude of decline typically accompanies a specific legislative setback: a committee rejection, a leadership statement shelving the bill, or a presidential veto threat. None of those events occurred here.
From 39% to 19%: Charting the Momentum Collapse
The decline was swift and largely unidirectional. The bill's current price of 19% is also its period low, meaning there has been no bounce whatsoever since the selling began. That absence of a rebound suggests the move is not noise or a single large trader liquidating a position. Multiple participants appear to be repricing the bill's prospects simultaneously, converging on a similar conclusion: 163 cosponsors or not, H.R. 1329 is unlikely to reach the president's desk this year.
The timing is worth noting. The February committee hearing came and went without advancing the bill to a markup, the next procedural step before a floor vote. Congress is now deep into March with a crowded legislative calendar dominated by budget reconciliation, defense authorization, and expiring tax provisions. Bills that don't secure floor time by midsummer in a session year rarely make it through both chambers before adjournment. Traders appear to be pricing the calendar, not the cosponsors.
Why Congressional Gridlock Swallows Even Popular Bills
Here is the structural reality that 163 cosponsors cannot override: floor time is a finite resource controlled by party leadership. The Speaker of the House and the Senate Majority Leader decide which bills get votes. A bill can have every member of Congress as a cosponsor and still die if leadership never schedules it. This is not hypothetical. According to GovTrack historical data, fewer than 7% of introduced bills in a typical Congress become law. Cosponsor counts correlate weakly with passage because the bottleneck is not support; it is scheduling.
H.R. 1329 faces a specific version of this problem. It authorizes a museum location on the National Mall Reserve, a decision that intersects with ongoing disputes over Smithsonian institutional priorities and public lands policy. The February hearing reportedly became a "proxy war" over competing Smithsonian museum proposals, suggesting that even within the committee, the bill's path forward is tangled with broader political negotiations. The Smithsonian's FY2026 budget request includes $19.136 million for the museum, building on $9.568 million appropriated in 2025. Federal funding is flowing. But appropriations and authorization are separate legislative tracks, and the authorization bill is the one stalling.
The Bull Case: What Would Need to Change for 19% to Be Wrong
The strongest argument against the current price is that 19% may underweight the possibility of H.R. 1329 being attached to a larger legislative vehicle. Must-pass bills like the National Defense Authorization Act or an omnibus spending package routinely carry smaller, broadly supported provisions across the finish line. A bill with 163 bipartisan cosponsors and no organized opposition is a prime candidate for exactly this kind of legislative hitchhiking.
There is also the Women's History Month factor. The Smithsonian American Women's History Museum is actively running programming, including a new oral history project called "We Do Declare: Women's Voices on Independence." Public visibility creates political incentive. Members of Congress who cosponsored H.R. 1329 have a built-in talking point during March and could push leadership to act. If the bill gets bundled into a year-end omnibus or continuing resolution, 19% will look like a steal.
What the Market Is Really Saying
The 19% price is not a verdict on the Women's History Museum's merits. It is a verdict on Congressional dysfunction. Traders are making a structural bet: that the 119th Congress will fail to convert bipartisan goodwill into enacted law on a bill that requires floor time it may never receive. The museum itself continues to advance, with federal appropriations, active programming, and institutional momentum at the Smithsonian. But prediction markets do not price momentum. They price outcomes. And the outcome that matters here, a presidential signature by December 31, 2026, requires the bill to survive a gauntlet that has nothing to do with how many names appear on its cosponsor list.
At 19%, the market is offering roughly 4-to-1 odds against passage. Given the calendar constraints, the committee-level friction, and the absence of any leadership commitment to schedule a vote, that price looks defensible. It may even be generous. The omnibus scenario is the wildcard that keeps this above single digits. Without it, 163 cosponsors are just names on a page.